(PA-143) mQOL, a Text-based Remote Therapeutic Monitoring (RTM) Platform for Symptom (Sx) and Quality of Life (QoL) Tracking in Multiple Myeloma (MM): Interim Results from a Prospective Observational Study

Introduction: Real-time Sx and QoL data are critical in managing multiple myeloma (MM) patients. mQOL is an easy HIPAA-compliant text-based platform allowing patients to proactively provide their Sx and QoL data, which is communicated continuously to their healthcare provider (HCP). This may facilitate earlier recognition of status changes and enable more timely clinical interventions.

Methods:

Methods: We conducted a single-center study using the mQOL RTM platform. Fifty MM patients in three cohorts were enrolled- newly diagnosed (ND), relapsed/refractory (RR), and on maintenance (MAINT) therapy. Nine Sx questions texted to patients as follows according to their cohort:

< !NDMM: daily for 30 days  QW until done

<  RRMM: daily for 30 days  QW until done

< !MAINT: QW throughout

Additionally, 10 QoL questions selected from the EORTC-QLQ-30 instrument were texted QOW to all patients. We used EORTC scoring (1-Not at all; 4-Very much) to assess severity for all questions. Potential actionable events were defined as an increase of > 2 and any value of 4. Participants completed Sx and QoL check-ins by text for 90 days, with completion rates, response burden, and data utility analyzed.

Results:

Results: Patients were enrolled between Mar 27 and May 12, 2025 (median age 68 years [range, 47-91]; RRMM 38%, MAINT 59%, NDMM 3%) A total of 6090 questions were asked. Patients in the NDMM and RRMM cohorts averaged 31 questions/ patient/week. Those in the MAINT cohort averaged 14 questions/patient/week. Sx and QoL check-in completion rates were both > 97%. Average QoL scores were low with mean ratings for tiredness (1.64), pain (1.68), and psychosocial burden (1.74). Sx tracking revealed bone pain (1.55) and neuropathy (1.70) were the most frequent complaints. The median time on study was 5 weeks during which 108 potentially actionable events were identified. Time burden  to complete mQOL assessments was minimal, averaging < 3 minutes, and this frequent assessment of Sx’s and QoL via the platform allowed additional clinical insights into the effects of treatment and myeloma on patients.

Conclusions:

Conclusion: The mQOL platform demonstrated excellent feasibility, high patient adherence, and the potential for enhancing patient outcomes. Notably, the high number of potential actionable events flagged identifies clinically significant problems that can be immediately addressed by clinicians. mQOL offers the opportunity to gain a better understanding of the effect of treatments and the disease on myeloma patients in a more accurate manner. These data support validation of mQOL as a real-time, patient-centered RTM tool to optimize Sx management and QoL outcomes for MM patients. Expansion into a large, multi-center study assessing different treatments and actionable interventions is being planned.